retatrutide singapore Retatrutide—A Game Changer in Obesity

Key Regulatory Points as of 2026: Not FDA-approved for any medical indication Cannot legally be sold as a drug, food, or dietary supplement for human consumption Legally sold as a "research chemical," not intended for human use Not a DEA-scheduled substance, so possession is not illegal (unlike anabolic steroids) Many medical clinics offer BPC-157 treatments despite lack of approval The FDA has expressed safety concerns due to the lack of human clinical trial data and the potential for adverse effects from unregulated manufacturing

Contraceptive absorption concerns for oral pills are likely amplified in this population given the pre-existing malabsorptive anatomy

Eli Lilly plans to begin orforgliprons review process for regulatory approval for weight loss in 2025 and for type 2 diabetes in 2026

These changes can create a physiological environment that favors regaining weight unless dietary and lifestyle strategies are adjusted

Clinical ended 3Q25 with 124k subscribers, up 60% y/y, generating $26mm of revenue, up 35% y/y